TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02417220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers Online 2015 Program
Description: Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Online 2015 Program
Description: Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Scale with Feedback
Description: Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
Study: NCT00042185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dissonance Eating Disorder Prevention Program
Description: In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Weight Intervention
Description: In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing Control Condition
Description: In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
Study: NCT03242096

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sirolimus coated balloon
Description: Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
Study: NCT02009449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Description: Day 1 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Description: Day 1 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Description: Day 1 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Description: Day 1 of every 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
Description: Intravenous administration on Day 1 and 2 of every 14 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel
Description: Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered orally daily continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab on Day 1 of each cycle (14 days = 1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/carboplatin
Description: gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
Study: NCT03288259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transnasal endoscopy
Description: Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics,Topical
Description: Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
Study: NCT04439903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based Simulation Tool
Description: Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
Study: NCT03917498

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single Pre-Operative Radiation Therapy - with Delayed Surgery
Description: Single Pre-Operative Radiation Therapy - with Delayed Surgery
Study: NCT03242096

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel coated balloon
Description: Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
Study: NCT01519427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02832726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Study: NCT00956241

Intervention type: PROCEDURE
Group type: OTHER
Intervention: j-pouch coloanal anastomosis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: side-to-end coloanal anastomosis
Study: NCT01841008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic
Description: Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo : Diprobase
Description: Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
Study: NCT00202410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille of Calmette-Guerin
Description: A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous administration of physiologic solution
Study: NCT02755740

Intervention type: OTHER
Group type: OTHER
Intervention: receiving age and gender-specific SC advice
Description: After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183).
Study: NCT02610088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
Study: NCT01494961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-oriented post-test HIV counseling
Description: COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
Study: NCT02016742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC5
Study: NCT04461847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous mastectomy
Description: Operating subcutaneous mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic subcutaneous mastectomy
Description: Operating endoscopic subcutaneous mastectomy
Study: NCT02739698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery-peritonectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery-peritonectomy
Study: NCT03836118

Intervention type: PROCEDURE
Intervention: Homologous intrauterine insemination (IUI)
Description: Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI.
Study: NCT02385461

Intervention type: DRUG
Intervention: Low Molecular Weight Heparins (LMWHs)

Intervention type: DRUG
Intervention: Low Molecular Weight Heparins (LMWHs)

Intervention type: DRUG
Intervention: Low Molecular Weight Heparins (LMWHs)
Study: NCT05921916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist
Study: NCT03016806

Intervention type: RADIATION
Group type: OTHER
Intervention: Total Body Irradiation 200 cGy
Description: Total Body Irradiation 200 cGy in one fraction

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 50 mg/kg or 60 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 50 mg/kg or 60 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 50 mg/kg or 60 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: 50 mg/kg or 60 mg/kg plus 10% loading dose

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: 50 mg/kg or 60 mg/kg plus 10% loading dose

Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: 50 mg/kg or 60 mg/kg plus 10% loading dose

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord Blood Infusion
Description: Intravenous infusion of cord blood stem cells

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord Blood Infusion
Description: Intravenous infusion of cord blood stem cells

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cord Blood Infusion
Description: Intravenous infusion of cord blood stem cells

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 0.8 mg/kg x 16 doses

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2/day x 5 or 40 mg/m2/day x 5

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2/day x 5 or 40 mg/m2/day x 5

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: 140 mg/m2
Study: NCT01378962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg orally once a day for 12 months
Study: NCT04085367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL 16.8% cream
Description: Day light photodynamic therapy with MAL 16.8% cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAL Vehicle Cream
Description: Day light photodynamic therapy with MAL vehicle cream
Study: NCT00543855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg Donepezil hydrochloride
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Donepezil hydrochloride
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Donepezil hydrochloride
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
Study: NCT00879944

Intervention type: OTHER
Intervention: Blood pressure
Description: Blood pressure will be measured once while patient is seated

Intervention type: OTHER
Intervention: Blood pressure
Description: Blood pressure will be measured once while patient is seated

Intervention type: OTHER
Intervention: Blood pressure
Description: Blood pressure will be measured once while patient is seated

Intervention type: OTHER
Intervention: Height
Description: Height will be measured in centimeters at the time of enrollment

Intervention type: OTHER
Intervention: Height
Description: Height will be measured in centimeters at the time of enrollment

Intervention type: OTHER
Intervention: Height
Description: Height will be measured in centimeters at the time of enrollment

Intervention type: OTHER
Intervention: Weight
Description: Weight will be measured in kilograms at enrollment

Intervention type: OTHER
Intervention: Weight
Description: Weight will be measured in kilograms at enrollment

Intervention type: OTHER
Intervention: Weight
Description: Weight will be measured in kilograms at enrollment

Intervention type: OTHER
Intervention: BMI
Description: Body Mass Index (BMI) will be calculated from a subject's height and weight

Intervention type: OTHER
Intervention: BMI
Description: Body Mass Index (BMI) will be calculated from a subject's height and weight

Intervention type: OTHER
Intervention: BMI
Description: Body Mass Index (BMI) will be calculated from a subject's height and weight

Intervention type: OTHER
Intervention: Waist Circumference
Description: Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm

Intervention type: OTHER
Intervention: Waist Circumference
Description: Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm

Intervention type: OTHER
Intervention: Waist Circumference
Description: Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
Study: NCT04867031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: One portion of semi-skimmed cow's milk (approx. 450mL), providing \~140µg of iodine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish
Description: One portion of cod (approx. 130g), providing \~140µg of iodine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed
Description: One portion of dried seaweed sheets (approx. 6g), providing \~140µg of iodine.
Study: NCT03442764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: MYK-461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: MYK-461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00321724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00719264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001(everolimus)
Description: 10 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alfa-2a
Description: dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg every 2 weeks
Study: NCT05921916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist
Study: NCT04082572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05921916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule solid microcrystalline cellulose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule solid microcrystalline cellulose